Lantheus (NASDAQ:LNTH) Updates FY24 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $6.65-6.70 for the period, compared to the consensus estimate of $6.66. The company issued revenue guidance of $1.51-1.52 billion, compared to the consensus revenue estimate of $1.52 billion. Lantheus also updated its FY 2024 guidance to 6.650-6.700 EPS.

Analysts Set New Price Targets

A number of analysts have recently commented on LNTH shares. Truist Financial restated a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday. B. Riley upped their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Redburn Atlantic started coverage on Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective for the company. Leerink Partners raised their target price on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research report on Thursday, July 11th. Finally, JMP Securities dropped their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Trading Down 0.9 %

Shares of LNTH traded down $0.82 during midday trading on Friday, reaching $87.50. The company had a trading volume of 1,617,957 shares, compared to its average volume of 993,185. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89. The firm has a 50 day simple moving average of $107.71 and a 200-day simple moving average of $95.52. The stock has a market cap of $6.08 billion, a PE ratio of 14.66 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $378.73 million during the quarter, compared to analyst estimates of $373.58 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. Research analysts forecast that Lantheus will post 5.99 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.10% of the stock is currently owned by corporate insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.